5/16/2013

A Series E funding round has brought in $35.5 million to Tokai Pharmaceuticals. The Massachusetts-based firm will use the money to expand an ongoing midstage trial of its prostate cancer drug galeterone, or TOK-001, to include castration-resistant patients.

Related Summaries